Bob Hutchens is the President & CEO of StemBioSys. StemBioSys markets a range of tools to researchers globally. These tools are used by Biopharmaceutical and Academic scientists in early stage drug efficacy and safety testing. In January of 2020, StemBioSys announced that it had acquired a majority stake in Cartox. Cartox , a spinout company from the University of Michigan, is led by Dr. Todd Herron, a faculty member in Michigan’s Frankel Cardiovascular Institute. Through their joint work, StemBioSys and Cartox have developed a major innovation in preclinical cardiac toxicity testing. The work was profiled in a recent publication in Nature Scientific Reports.
Prior to StemBioSys, Bob was Partner with Booz & Company (now a member of the PWC network and known as Strategy&) in New York.
During his nearly 25 years in management consulting, most of Bob’s work was with clients in the Life Sciences industry. Bob’s clients included a number of major pharmaceutical companies as well as a range of medical device and life science tool companies. While at Booz, Bob also spent many years working with Centers for Disease Control (CDC) and the President’s Emergency Program for Aids Relief (PEPFAR).
Bob has a Bachelor of Business Administration from the Ross School of Business at The University of Michigan with Distinction and a Master of Business Administration in Finance and Operations from the Wharton School at the University of Pennsylvania. He is married to Randi Brosterman Hutchens – also an alumnae of the MBA program at the Wharton School. Bob has two children – both of whom are currently in college (unfortunately, neither is a Wolverine). Bob and Randi have homes in both Chappaqua, NY and San Antonio, TX.